# Semaglutide and Days Spent in Hospital

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/semaglutide-and-days-spent-in-hospital

> A prespecified analysis of SELECT found hospital days falling from 176.2 to 157.2 per 100 patient-years. It is a modest number from a randomized trial, which is what makes it trustworthy.

## Key points

- 157.2 vs 176.2 days hospitalized per 100 patient-years; rate ratio 0.89.
- It comes from a randomized trial, which removes the objection that dogs observational findings.
- Consistent across BMI, age and sex; no subgroup carried the effect.
- A modest number is more trustworthy than a dramatic one.

Cardiovascular trials report hazard ratios for events most people will never have. A prespecified analysis of the SELECT trial measured something more recognizable: how much time participants spent in hospital. Semaglutide cut it from **176.2 to 157.2 days per 100 patient-years**.[1]

## What was measured

SELECT randomized 17,604 people with obesity and established cardiovascular disease but without diabetes. We covered its main result, fewer major cardiovascular events, in [the evidence-duration article](https://glpwatchdog.org/research/how-long-is-the-evidence-actually). This analysis asked a different question of the same trial.

*Days hospitalized per 100 patient-years in SELECT.*

| Measure | Semaglutide | Placebo | Rate ratio |
| --- | --- | --- | --- |
| Any indication | 157.2 | 176.2 | 0.89 (95% CI 0.82–0.98), p=0.01 |
| Serious adverse events | 137.6 | 153.9 | 0.89 (95% CI 0.81–0.98), p=0.02 |

No heterogeneity appeared across BMI, age or sex subgroups. The reduction was consistent rather than concentrated in one group.[1]

## Why days in hospital is a better unit

A hazard ratio for a composite cardiovascular endpoint is hard to feel. Days in hospital is not. It captures severity as well as frequency, since a long admission counts for more than a short one. And it adds up everything that put someone in a bed, not only the events a trial was designed to count.

> The cohort had a high rate of hospital admissions to begin with. That is what makes an 11% relative reduction worth stating in days.

It is also the outcome that translates most directly into cost, which is usually argued about separately from clinical benefit. Here one number covers both: time in hospital is expensive for health systems and disruptive for people.

## What kind of evidence this is

The analysis was prespecified and exploratory, and the two words mean different things. Prespecified means the analysis was planned before the data were seen, so it is not a result someone went looking for afterward. Exploratory means it was not the endpoint the trial was powered to answer, so it should be read as supportive rather than definitive.

What it has that most hospitalization findings do not is randomization. We have covered several observational studies reporting fewer hospitalizations on these drugs, in [people with cancer](https://glpwatchdog.org/research/glp1s-in-people-being-treated-for-cancer) and in [infection risk](https://glpwatchdog.org/research/glp1-pneumonia-and-sepsis-risk). Every one of them carries the objection that healthier people get prescribed newer drugs. Randomization removes that objection.

> **This is a good example of a modest number being more trustworthy than a dramatic one.** An 11% relative reduction in hospital days is the size of effect a real drug produces. When observational data show 47%, 78% or 91% mortality reductions, the size itself is the warning, a point we set out in [when a hazard ratio is too good](https://glpwatchdog.org/research/when-a-hazard-ratio-is-too-good).

## Frequently asked questions

### Does semaglutide reduce hospital admissions?

In a prespecified analysis of the SELECT trial, days hospitalized fell from 176.2 to 157.2 per 100 patient-years, a rate ratio of 0.89. Hospitalizations for serious adverse events fell similarly.

### Why measure days rather than admissions?

Days capture severity as well as frequency, and they add up everything that put someone in a bed, not only the events the trial was designed to count. It is also the number that translates most directly into cost.

### How strong is this finding?

It is prespecified but exploratory. It was planned in advance, so it is not a result found by searching, but it was not the endpoint the trial was powered for. What makes it more reliable than similar observational findings is that it comes from a randomized trial.

### Did it help some groups more than others?

No heterogeneity was observed across BMI, age or sex. The reduction was consistent rather than concentrated in a subgroup.

### Is an 11% reduction meaningful?

In a cohort with a high baseline admission rate, nineteen fewer days per hundred patient-years is a real amount of time. It is also the size of effect real drugs produce, which is part of why it is more believable than the much larger numbers observational studies sometimes report.

## References

1. Nicholls SJ, Ryan DH, Deanfield J, et al. Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial. JAMA Cardiology. 2026. PMID: 41433034. https://pubmed.ncbi.nlm.nih.gov/41433034/

---

Cite as: GLP Watchdog, Nora Bissett, "Semaglutide and Days Spent in Hospital", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/semaglutide-and-days-spent-in-hospital

Canonical HTML page: https://glpwatchdog.org/research/semaglutide-and-days-spent-in-hospital

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
